Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis

Bone Marrow Transplantation volume 51, pages 698–704 (2016)Cite this article

Subjects

Abstract

There is currently a major concern regarding the optimal immunosuppression therapy to be administered after hematopoietic stem cell transplantation (HSCT) to reduce both the toxicity of GvHD and the rate of relapse. We report the outcome of high-risk leukemia children transplanted with a new way of managing cyclosporine (CsA)-based GvHD prophylaxis. A total of 110 HSCT in 109 ALL or AML children who received CsA without mycophenolate or methotrexate in matched related as well as in matched or mismatched unrelated stem cell transplantation were included. CsA dosage regimens were individualized to obtain specific trough blood concentrations values. The incidences of grade I–II and III–IV acute GvHD were 69.1% and 1.8%, respectively, and 8.4% for chronic GvHD. GvHD was neither more frequent nor severe in unrelated than in related HSCT. GvHD occurred in 87% of patients with a mean CsA trough concentration ⩽120 ng/mL versus 43% with concentration >120 ng/mL (P<0.0001). Five-year disease-free survival (DFS) and overall survival were 78% and 83.6%, respectively. DFS was 76.9% for ALL and 80.4% for AML patients. There was no difference in DFS between matched siblings and matched unrelated or mismatched unrelated HSCT. DFS in patients with minimal residual disease (MRD) ⩾10−3 and in those with MRD <10−3 before SCT was comparable. Our results indicate that a GvHD prophylaxis regimen based on CsA without mycophenolate or methotrexate is safe and effective whatever the donor compatibility is. These results suggest that GvL effect may be enhanced by this strategy of GvHD prophylaxis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979; 300: 1068–1073.

    CAS  PubMed  Google Scholar 

  2. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    CAS  PubMed  Google Scholar 

  3. Jiang YZ, Kanfer EJ, Macdonald D, Cullis JO, Goldman JM, Barrett AJ . Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant 1991; 8: 253–258.

    CAS  PubMed  Google Scholar 

  4. Keever CA, Klein J, Leong N, Copelan EA, Avalos BR, Kapoor N et al. Effect of GVHD on the recovery of NK cell activity and LAK precursors following BMT. Bone Marrow Transplant 1993; 12: 289–295.

    CAS  PubMed  Google Scholar 

  5. Kataoka I, Kami M, Takahashi S, Kodera Y, Miyawaki S, Hirabayashi N et al. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. Bone Marrow Transplant 2004; 34: 711–719.

    Article  CAS  PubMed  Google Scholar 

  6. Peters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F et al. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 2000; 26: 405–411.

    Article  CAS  PubMed  Google Scholar 

  7. Lee KH, Choi SJ, Lee JH, Kim S, Seol M, Lee YS et al. Cyclosporine alone versus cyclosporine plus methotrexate for post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation: a randomized prospective study. Bone Marrow Transplant 2004; 34: 627–636.

    Article  CAS  PubMed  Google Scholar 

  8. Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH et al. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003; 32: 777–784.

    Article  CAS  PubMed  Google Scholar 

  9. Ram R, Storer B, Mielcarek M, Sandmaier BM, Maloney DG, Martin PJ et al. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 414–422.

    Article  CAS  PubMed  Google Scholar 

  10. Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M . Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model. Pharm Res 2011; 28: 531–539.

    Article  PubMed  Google Scholar 

  11. Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003; 32: 881–887.

    Article  CAS  PubMed  Google Scholar 

  12. Willemze AJ, Press RR, Lankester AC, Egeler RM, den Hartigh J, Vossen JM . CsA exposure is associated with acute GVHD and relapse in children after SCT. Bone Marrow Transplant 2010; 45: 1056–1061.

    Article  CAS  PubMed  Google Scholar 

  13. Bleyzac N . The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine. Fundam Clin Pharmacol 2008; 22: 605–608.

    Article  CAS  PubMed  Google Scholar 

  14. Domenech C, Suciu S, De Moerloose B, Mazingue F, Plat G, Ferster A et al. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica 2014; 99: 1220–1227.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012; 13: 936–945.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 2010; 116: 2644–2650.

    Article  CAS  PubMed  Google Scholar 

  17. Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010; 28: 2339–2347.

    Article  CAS  PubMed  Google Scholar 

  18. Petit A, Ducassou S, Leblanc T, Pasquet M, Rousseau A, Ragu C et al. Relevance of a one-year maintenance therapy with interleukin-2 in the treatment of childhood acute myeloid leukemia: results from the French Multicenter, Phase III, Randomized Controlled SFCE Trial, ELAM02. Blood 2014; 124: 378.

    Google Scholar 

  19. Kaspers GJ, Zimmermann M, Reinhardt D, Gibson BE, Tamminga RY, Aleinikova O et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 2013; 31: 599–607.

    Article  CAS  PubMed  Google Scholar 

  20. Dessars B, Cotton F, Thiry P, Gulbis B . Comparison of automated ACMIA and EMIT immunoassays for whole blood cyclosporin monitoring. Clin Lab 2003; 49: 135–140.

    CAS  PubMed  Google Scholar 

  21. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  22. van der Velden VH, van der Sluijs-Geling A, Gibson BE, te Marvelde JG, Hoogeveen PG, Hop WC et al. Clinical significance of flow cytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010; 24: 1599–1606.

    Article  CAS  PubMed  Google Scholar 

  23. Garand R, Beldjord K, Cavé H, Fossat C, Arnoux I, Asnafi V et al. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. Leukemia 2013; 27: 370–376.

    Article  CAS  PubMed  Google Scholar 

  24. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543–552.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gandemer V, Pochon C, Oger E, Dalle JH, Michel G, Schmitt C et al. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol. Br J Haematol 2014; 165: 392–401.

    Article  PubMed  Google Scholar 

  26. Zhang P, Chen BJ, Chao NJ . Prevention of GVHD without losing GVL effect: windows of opportunity. Immunol Res 2011; 49: 49–55.

    Article  PubMed  Google Scholar 

  27. Balduzzi A, Di Maio L, Silvestri D, Songia S, Bonanomi S, Rovelli A et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? Br J Haematol 2014; 164: 396–408.

    Article  CAS  PubMed  Google Scholar 

  28. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood 2013; 122: 3863–3870.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Dini G, Zecca M, Balduzzi A, Messina C, Masetti R, Fagioli F et al. No difference in outcome between children and adolescents transplanted for acute lymphoblasticleukemia in second remission. Blood 2011; 118: 6683–6690.

    Article  CAS  PubMed  Google Scholar 

  30. Fagioli F, Quarello P, Zecca M, Lanino E, Rognoni C, Balduzzi A et al. Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. Haematologica 2013; 98: 1273–1281.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Locatelli F, Masetti R, Rondelli R, Zecca M, Fagioli F, Rovelli A et al. Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the AIEOP AML-2002/01 study. Bone Marrow Transplant 2015; 50: 181–188 Erratum in: Bone Marrow Transplant 2015; 50: 320.

    Article  CAS  PubMed  Google Scholar 

  32. Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors—the ALL-SCT-BFM-2003 Trial. J Clin Oncol 2015; 33: 1265–1274.

    Article  CAS  PubMed  Google Scholar 

  33. Zheng C, Tang B, Tong J, Liu H, Geng L, Wang X et al. Unrelated cord blood transplantation for central nervous system relapse in high-risk childhood acute lymphoblastic leukemia. Ann Hematol 2013; 92: 1665–1673.

    Article  CAS  PubMed  Google Scholar 

  34. Koh KN, Park M, Kim BE, Bae KW, Im HJ, Seo JJ . Favorable outcomes after allogeneic hematopoietic stem cell transplantation in children with high-risk or advanced acute myeloid leukemia. J Pediatr Hematol Oncol 2011; 33: 281–288.

    Article  PubMed  Google Scholar 

  35. Nemecek ER, Ellis K, He W, Bunin NJ, Bajwa RS, Cheerva A et al. Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission. Biol Blood Marrow Transplant 2011; 17: 1833–1840.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Thiel E, Zhang MJ, Davies SM, Logan B, Tiedemann K, Eapen M et al. Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012; 18: 1204–1210.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Weiss M, Steinbach D, Zintl F, Beck J, Gruhn B . Superior outcome using cyclosporin A alone versus cyclosporin A plus methotrexate for post-transplant immunosuppression in children with acute leukemia undergoing sibling hematopoietic stem cell transplantation. J Cancer Res Clin Oncol 2015; 141: 1089–1094.

    Article  CAS  PubMed  Google Scholar 

  38. Conter V, Valsecchi MG, Parasole R, Putti MC, Locatelli F, Barisone E et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood 2014; 123: 1470–1478.

    Article  CAS  PubMed  Google Scholar 

  39. Sutton R, Shaw PJ, Venn NC, Law T, Dissanayake A, Kilo T et al. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol 2015; 168: 395–404.

    Article  PubMed  Google Scholar 

  40. Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 2013; 122: 170–178.

    Article  CAS  PubMed  Google Scholar 

  41. Wang H, Grzywacz B, Sukovich D, McCullar V, Cao Q, Lee AB et al. The unexpected effect of cyclosporin A on CD56+CD16− and CD56+CD16+ natural killer cell subpopulations. Blood 2007; 110: 1530–1539.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Eissens DN, Van Der Meer A, Van Cranenbroek B, Preijers FW, Joosten I . Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects onNK cell phenotype. Am J Transplant 2010; 10: 1981–1990.

    Article  CAS  PubMed  Google Scholar 

  43. Ohata K, Espinoza JL, Lu X, Kondo Y, Nakao S . Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. Biol Blood Marrow Transplant 2011; 17: 205–213.

    Article  CAS  PubMed  Google Scholar 

  44. Meehan AC, Mifsud NA, Nguyen TH, Levvey BJ, Snell GI, Kotsimbos TC et al. Impact of commonly used transplant immunosuppressive drugs on human NK cell function is dependent upon stimulation condition. PLoS One 2013; 8: e60144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Brenner BG, Friedman G, Margolese RG . The relationship of clinical status and therapeutic modality to natural killer cell activity in human breast cancer. Cancer 1985; 56: 1543–1548.

    Article  CAS  PubMed  Google Scholar 

  46. Rosenthal GJ, Germolec DR, Lamm KR, Ackermann MF, Luster MI . Comparative effects on the immune system of methotrexate and trimetrexate. Int J Immunopharmacol 1987; 9: 793–801.

    Article  CAS  PubMed  Google Scholar 

  47. Matheson DS, Green B, Hoar DI . The influence of methotrexate and thymidine on the human natural killer cell function in vitro. J Immunol 1983; 131: 1619–1621.

    CAS  PubMed  Google Scholar 

  48. Stein CM, Murray JJ, Wood AJ . Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem 1999; 45: 1477–1484.

    CAS  PubMed  Google Scholar 

  49. van Rood JJ, Scaradavou A, Stevens CE . Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation. Proc Natl Acad Sci U S A 2012; 109: 2509–2514.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Vitale C, Cottalasso F, Montaldo E, Moretta L, Mingari MC . Methylprednisolone induces preferential and rapid differentiation of CD34+ cord blood precursors toward NK cells. Int Immunol 2008; 20: 565–575.

    Article  CAS  PubMed  Google Scholar 

  51. Vitale C, Chiossone L, Cantoni C, Morreale G, Cottalasso F, Moretti S et al. The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity. Eur J Immunol 2004; 34: 3028–3038.

    Article  CAS  PubMed  Google Scholar 

  52. Giebel S, Dziaczkowska J, Wojnar J, Wojnar J, Krawczyk-Kulis M, Markiewicz M et al. The impact of immunosuppressive therapy on an early quantitative NK cell reconstitution after allogeneic haematopoietic cell transplantation. Ann Transplant 2005; 10: 29–33.

    PubMed  Google Scholar 

  53. Veys P, Wynn RF, Ahn KW, Samarasinghe S, He W, Bonney D et al. Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. Blood 2012; 119: 6155–6161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B et al. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood 2014; 123: 1615–1620.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012; 120: 468–472.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP et al. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Biol Blood Marrow Transplant 2012; 18: 963–968.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013; 122: 1813–1821.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll W et al. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transplant 2015; 50: 1173–1179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pediatric Hematology and Oncology, Hospices Civils de Lyon and Claude Bernard Lyon 1 University, Lyon, France

    N Bleyzac, D Cuzzubbo, C Rénard, N Garnier, C Domenech, M-P Goutagny & Y Bertrand

  2. EMR 3738, Team 2 - PK/PD Modeling in Oncology, Lyon-Sud Faculty of Medicine, Oullins, France

    N Bleyzac

  3. Laboratory of Histocompatibility, French Agency of Blood (EFS), Lyon, France

    V Dubois

  4. Laboratory of Immunology, Lyon Sud University Hospital, Lyon, France

    A Plesa

  5. Laboratory of Molecular Biology, University Hospital, Lille, France

    N Grardel

  6. Institute of Pharmaceutical and Biological Sciences, Lyon 1 University, Lyon, France

    S Goutelle & A Janoly-Duménil

Authors
  1. N Bleyzac
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Cuzzubbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Rénard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Garnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V Dubois
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Domenech
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M-P Goutagny
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Plesa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N Grardel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Goutelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Janoly-Duménil
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Y Bertrand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N Bleyzac.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bleyzac, N., Cuzzubbo, D., Rénard, C. et al. Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis. Bone Marrow Transplant 51, 698–704 (2016). https://doi.org/10.1038/bmt.2015.350

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.350

This article is cited by

Search

Advanced search

Quick links